Fight Aging! Newsletter, August 7th 2023
In conclusion, here, we demonstrate a novel mechanism for ESC-EVs to protect cells from senescence. However, whether ESC-EVs rejuvenate aged mice via miR-15b-5p and miR-290a-5p remains unknown. Next, we plan to use miR-15b-5p and miR-290a-5p antagonists while treating aged mice with ESC-EVs to further investigate the mechanism by which ESC-EVs resist aging in vivo.
« Back to Top
Fatty Acid Metabolism as a Commonality in Different Approaches to Slowing Aging
https://www.fightaging.org/archives/2023/08/fatty-acid-metabolism-as-a-commonality-in-different-approaches-to-slowing-aging/
It seem...
Source: Fight Aging! - August 6, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Hoping for Gut Microbiome Rejuvenation to Reduce the Incidence of Alzheimer's Disease
It has only comparatively recently become widely understood that the microbial populations making up the gut microbiome change in abundance in characteristic ways with age. Similarly, that the gut microbiome tends to be different in characteristic ways in older people who go on to develop Alzheimer's disease. It remains to be seen as to whether an altered gut microbiome is a meaningful contributing cause to Alzheimer's disease, such as via increased chronic inflammation, or a side effect of some other meaningful contribution, such as the aging of the immune system. At the least, it presents a novel way to assess risk in ol...
Source: Fight Aging! - August 4, 2023 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
This Personality Trait Cuts Alzheimer ’ s Risk In Half
A study of hundreds of nuns and monks reveals which trait cuts Alzheimer's risk in half. (Source: PsyBlog | Psychology Blog)
Source: PsyBlog | Psychology Blog - August 2, 2023 Category: Psychiatry & Psychology Authors: Jeremy Dean Tags: Dementia Personality Source Type: blogs
Price tag for a questionable Alzheimer ’s treatment: $109,000 per patient, per year. Unclear yet: For how many years?
The real costs of the new Alzheimer’s drug, Leqembi — and why taxpayers will foot much of the bill (CBS News):
The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S. health care system billions annually even as it remains out of reach for many of the lower-income seniors most likely to suffer from dementia.
Medicare and Medicaid patients will make up 92% of the market for lecanemab, according to Eisai Co., which sells the drug under the brand name Leqembi. In addition to the company’s $26,500 annual price tag for the drug, treatment could cost U.S. taxpayers $82,500 per pati...
Source: SharpBrains - August 2, 2023 Category: Neuroscience Authors: SharpBrains Tags: Brain/ Mental Health Alzheimers-disease amyloid plaques brain hemorrhaging brain scans brain swelling dementia lecanemab Leqembi Medicaid Medicare PET-scan taxpayers Source Type: blogs
NRF2 in the Oxidative Stress of Alzheimer's Disease
There are many ways of looking at the pathology of Alzheimer's disease, as it is very complex, layered condition. One of these viewpoints is to note that levels of oxidative stress increase in the Alzheimer's brain, stressing and killing cells. Researchers here report on their investigation of changes in the NRF2-centered regulation of cellular antioxidant systems that take pace in the Alzheimer's brain. A decline in antoxidants accelerates the progression of cell death and dysfunction, but this can be slowed or prevented by suitably targeted intervention aimed at maintaining NRF2 activity. Whether or not this is too far d...
Source: Fight Aging! - August 1, 2023 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Postmenopausal Hormone Treatment Correlates with Increased Dementia Risk
We report a nationwide study on the association between menopausal hormone therapy and development of dementia. 5,589 incident cases of dementia and 55,890 age matched controls were identified between 2000 and 2018 from a population of all Danish women aged 50-60 years in 2000 with no history of dementia or contraindications for use of menopausal hormone therapy.
Compared with people who had never used treatment, people who had received oestrogen-progestin therapy had an increased rate of all cause dementia (hazard ratio 1.24). Increasing durations of use yielded higher hazard ratios, ranging from 1.21 for one year ...
Source: Fight Aging! - July 31, 2023 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, July 31st 2023
In conclusion, an SBP level below 130 mmHg was found to be associated with longevity among older women. The longer SBP was controlled at a level between 110 and 130 mmHg, the higher the survival probability to age 90. Preventing age-related rises in SBP and increasing the time with controlled BP levels constitute important measures for achieving longevity.
« Back to Top (Source: Fight Aging!)
Source: Fight Aging! - July 30, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
How Simple Vibrations Could Help Treat Alzheimer ’ s (M)
The study is the latest in a line of research suggesting that gamma waves in different modalities could help fight Alzheimer's, the most common form of dementia. (Source: PsyBlog | Psychology Blog)
Source: PsyBlog | Psychology Blog - July 27, 2023 Category: Psychiatry & Psychology Authors: Jeremy Dean Tags: Dementia subscribers-only Source Type: blogs
The Ketone Body β-hydroxybutyrate is Involved in Clearance of Amyloid-β
Researchers here note an interesting role for one of the common ketone bodies found in mammalian biochemistry, in that it provokes clearance of amyloid-β via its interaction with that molecule. An increase in misfolded amyloid-β is involved in the early stages of Alzheimer's disease, and seems likely to cause some fraction of the pathology of that condition. If comparatively simple approaches could keep amyloid-β levels low in later life, then the incidence of Alzheimer's disease might be reduced. That said, while the mechanism described here is interesting, it doesn't mean that the effect size, relative to other mechan...
Source: Fight Aging! - July 26, 2023 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Donanemab Slows Progression of Earlier, Less Severe Alzheimer's Disease
Several immunotherapies targeting amyloid-β in the brain have now been shown to modestly slow the progression of Alzheimer's disease if applied at an earlier stage of the condition. This is a long way removed from a cure, particularly given the potentially severe side-effects that accompany brain-targeted monoclonal antibody therapies. Alzheimer's is a complicated condition, and it seems clear that removing amyloid-β does too little on its own to reduce pathology in the brain. It is contributing, but it is not the only contribution, or perhaps not even the most important contribution. More will be needed in parallel, suc...
Source: Fight Aging! - July 24, 2023 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, July 24th 2023
In this study, we tested the hypothesis that periodontal disease (PD) as a source of infection alters inflammatory activation and Aβ phagocytosis by the microglial cells.
Experimental PD was induced using ligatures in C57BL/6 mice for 1, 10, 20, and 30 days to assess the progression of PD. Animals without ligatures were used as controls. Ligature placement caused progressive periodontal disease and bone resorption that was already significant on day 1 post-ligation and continued to increase until day 30. The severity of periodontal disease increased the frequency of activated microglia in the brains on day 30 by 36...
Source: Fight Aging! - July 23, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Reviewing What is Known of the Biochemistry of Klotho Relevant to Effects on Life Span
Increased klotho expression increases longevity in mice, while reduced klotho expression accelerates aging. The most well studied effects of klotho on organ function involve the kidney and brain, where in both cases it appears protective via a number of different mechanisms. Unfortunately, klotho expression declines with age. Whether treating humans with therapies that increase levels of klotho will produce effects that are as large as those observed in mice remains to be seen. Programs that might lead to treatments remain at a preclinical stage of development, though recently advanced to the point of testing in non-human ...
Source: Fight Aging! - July 21, 2023 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
How A Daytime Nap Affects Your Brain Volume (M)
There is some stigma around napping, perhaps partly because excessive daytime napping can be a sign of Alzheimer's. (Source: PsyBlog | Psychology Blog)
Source: PsyBlog | Psychology Blog - July 20, 2023 Category: Psychiatry & Psychology Authors: Jeremy Dean Tags: Sleep subscribers-only Source Type: blogs
5 Ways Data (and Storage) are Powering the Evolution of Healthcare
The following is a guest article by Doug McLoughlin, Regional Manager at Western Digital
Healthcare technology is finally catching up with a digital revolution that’s been well underway for over a decade in other industries. The transformation was accelerated in the last three years when confined to our homes for months on end, doctors and patients alike turned to technology to try and stay healthy and connected.
From medical to consumer-grade devices, millions of new endpoints emerged, generating new volumes of data. Ranging from improving individual health to better patient outcomes to enabling more advanced research, ...
Source: EMR and HIPAA - July 20, 2023 Category: Information Technology Authors: Guest Author Tags: Analytics/Big Data Health IT Company Healthcare IT IT Infrastructure and Dev Ops AI Data Storage Doug McLoughlin Healthcare Data Healthcare Data Storage Improving Patient Outcomes ML Reducing Costs RPM Western Digital Source Type: blogs
